CN108524550B - Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 - Google Patents
Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 Download PDFInfo
- Publication number
- CN108524550B CN108524550B CN201810367027.2A CN201810367027A CN108524550B CN 108524550 B CN108524550 B CN 108524550B CN 201810367027 A CN201810367027 A CN 201810367027A CN 108524550 B CN108524550 B CN 108524550B
- Authority
- CN
- China
- Prior art keywords
- staphylococcal enterotoxin
- vaccine
- animal
- liquid aerosol
- toxoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004072 lung Anatomy 0.000 title claims abstract description 52
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 52
- 229940031572 toxoid vaccine Drugs 0.000 title abstract description 15
- 238000010172 mouse model Methods 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000443 aerosol Substances 0.000 title abstract description 5
- 231100000655 enterotoxin Toxicity 0.000 claims abstract description 128
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims abstract description 125
- 229960005486 vaccine Drugs 0.000 claims abstract description 62
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 239000008263 liquid aerosol Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000002158 endotoxin Substances 0.000 claims abstract description 20
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 20
- 238000010171 animal model Methods 0.000 claims abstract description 17
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 14
- 238000012216 screening Methods 0.000 claims abstract description 9
- 206010070834 Sensitisation Diseases 0.000 claims abstract description 5
- 230000008313 sensitization Effects 0.000 claims abstract description 5
- 239000002671 adjuvant Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 13
- 231100000636 lethal dose Toxicity 0.000 claims description 10
- 229940126585 therapeutic drug Drugs 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000010534 mechanism of action Effects 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 17
- 238000002649 immunization Methods 0.000 abstract description 15
- 230000003053 immunization Effects 0.000 abstract description 15
- 230000001900 immune effect Effects 0.000 abstract description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 229920001993 poloxamer 188 Polymers 0.000 description 7
- 229940044519 poloxamer 188 Drugs 0.000 description 7
- 206010040070 Septic Shock Diseases 0.000 description 6
- 206010044248 Toxic shock syndrome Diseases 0.000 description 6
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 206010035669 Pneumonia aspiration Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000002325 super-antigenic effect Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810367027.2A CN108524550B (zh) | 2018-04-23 | 2018-04-23 | Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810367027.2A CN108524550B (zh) | 2018-04-23 | 2018-04-23 | Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108524550A CN108524550A (zh) | 2018-09-14 |
CN108524550B true CN108524550B (zh) | 2019-12-24 |
Family
ID=63479257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810367027.2A Active CN108524550B (zh) | 2018-04-23 | 2018-04-23 | Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108524550B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111588841A (zh) * | 2019-02-21 | 2020-08-28 | 中国人民解放军军事科学院军事医学研究院 | 一种可气溶胶化的seb类毒素疫苗干粉吸入剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103160519A (zh) * | 2013-03-12 | 2013-06-19 | 张婉茹 | 金黄色葡萄球菌肠毒素b免疫制剂及其制备方法和应用 |
CN103781487A (zh) * | 2011-04-20 | 2014-05-07 | 米科生物公司 | 用于增强免疫应答的组合物和方法 |
-
2018
- 2018-04-23 CN CN201810367027.2A patent/CN108524550B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103781487A (zh) * | 2011-04-20 | 2014-05-07 | 米科生物公司 | 用于增强免疫应答的组合物和方法 |
CN103160519A (zh) * | 2013-03-12 | 2013-06-19 | 张婉茹 | 金黄色葡萄球菌肠毒素b免疫制剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108524550A (zh) | 2018-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189898A (zh) | 铜绿假单胞菌疫苗及其制备方法 | |
JP2010523711A (ja) | 結核のワクチンおよびその使用方法 | |
CN112843228B (zh) | 一种兔巴氏杆菌病二价灭活疫苗及其制备方法 | |
AU2013351213B2 (en) | Vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida | |
CN108524550B (zh) | Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 | |
Rasouli et al. | Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against COVID-19 | |
US9642905B2 (en) | Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica | |
Bain et al. | Parenteral vaccination of calves against the cattle lungworm Dictyocaulus viviparus | |
JP6867623B2 (ja) | 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法 | |
CN105497885B (zh) | 一种亚单位疫苗及其制备方法和应用 | |
US11717566B2 (en) | Brucella canis vaccine for dogs | |
KR20220133633A (ko) | SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도 | |
CN1332018C (zh) | 冻干母牛分枝杆菌制剂(微卡)及其制备方法和用途 | |
RU2396978C1 (ru) | Способ профилактики развития лейкоза крупного рогатого скота | |
CN109078177B (zh) | 一种预防结核病的疫苗及联合用药物和制备方法、应用 | |
CN105749265B (zh) | 一种二价炭疽疫苗 | |
JPWO2016017620A1 (ja) | サルモネラワクチン | |
Neranja et al. | A mini-review on the different types of covid-19 vaccines in use | |
CN115918608A (zh) | 手持式气溶胶吸入嗜麦芽窄食单胞菌的小鼠肺部感染模型的构建方法及其应用 | |
Żakowska et al. | Vaccines Against Anthrax–Selected Research | |
CN111588841A (zh) | 一种可气溶胶化的seb类毒素疫苗干粉吸入剂 | |
Bull | The Prophylactic and Therapeutic Properties of the Antitoxin for Bacillus welchii | |
RU2292916C1 (ru) | Способ иммунопрофилактики острых респираторных болезней телят | |
Rybalkin | The study of the therapeutic action of the cell-associated antigens of Candida albicans and Candida tropicalis fungi | |
CN113262297A (zh) | 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Hao Huaijie Inventor after: Wang Xiaoyi Inventor after: Yin Zhe Inventor after: Zhao Yuee Inventor after: Yu Xuedong Inventor after: Xiong Xiaolu Inventor after: Jiao Jun Inventor after: Jin Aijun Inventor after: Hu Lingfei Inventor after: Zhou Dongsheng Inventor after: Yang Huiying Inventor after: Sun Yansong Inventor after: Qiu Yefeng Inventor after: Gao Bo Inventor after: Fa Yunzhi Inventor after: Yang Wenhui Inventor after: Feng Junxia Inventor before: Hao Huaijie Inventor before: Wang Xiaoyi Inventor before: Yin Zhe Inventor before: Zhao Yuee Inventor before: Yu Xuedong Inventor before: Xiong Xiaolu Inventor before: Jiao Jun Inventor before: Jin Aijun Inventor before: Hu Lingfei Inventor before: Zhou Dongsheng Inventor before: Yang Huiying Inventor before: Sun Yansong Inventor before: Qiu Yefeng Inventor before: Gao Bo Inventor before: Fa Yunzhi Inventor before: Yang Wenhui Inventor before: Feng Junxia |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Huiying Inventor after: Wang Xiaoyi Inventor after: Yin Zhe Inventor after: Zhao Yuee Inventor after: Yu Xuedong Inventor after: Xiong Xiaolu Inventor after: Jiao Jun Inventor after: Jin Aijun Inventor after: Hu Lingfei Inventor after: Zhou Dongsheng Inventor after: Hao Huaijie Inventor after: Sun Yansong Inventor after: Qiu Yefeng Inventor after: Gao Bo Inventor after: Fa Yunzhi Inventor after: Yang Wenhui Inventor after: Feng Junxia Inventor before: Hao Huaijie Inventor before: Wang Xiaoyi Inventor before: Yin Zhe Inventor before: Zhao Yuee Inventor before: Yu Xuedong Inventor before: Xiong Xiaolu Inventor before: Jiao Jun Inventor before: Jin Aijun Inventor before: Hu Lingfei Inventor before: Zhou Dongsheng Inventor before: Yang Huiying Inventor before: Sun Yansong Inventor before: Qiu Yefeng Inventor before: Gao Bo Inventor before: Fa Yunzhi Inventor before: Yang Wenhui Inventor before: Feng Junxia |